MedPath

Phase 1 study of TM5509 -placebo controlled multiple dose study in male healthy adult subjects

Phase 1
Conditions
Recover of hematogenesis after cord blood transplantation
Registration Number
JPRN-UMIN000015590
Lead Sponsor
Tohoku university school of medicine, molecular medicine and therapy, Toshio Miyata
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Male
Target Recruitment
18
Inclusion Criteria

Not provided

Exclusion Criteria

1.Male Japanese 2.From 20 years old to 45 years old at voluntary written consent 3.From 50.0 kg to 85.0 kg and from 18.5 to 25.0 of BMI at screening 4.Voluntary written consent by themselves is given before screening. 1.History of liver diseases, cardiovascular diseases, respiratory diseaases, gastroenteric diseases, kidney diseases, cerebralvascular diseases, cancer 2.Known hypersensitivity to some drugs and foods 3.Treatment by other doctors (included supplement) within 14 days before screening 4.Treatment with any investigational compound within 120 days before screening 5.History of TM5509 administration 6.History of blood taken *>= 1200ml of all blood within 1 year before screening *>= 400ml of all blood with 84 days before screening *>= 200ml of all blood within 14 days before screening 7.Smoking status and treatment with anti-nicotine agents 8.Known active chronic hepatitis B or C, active syphilis and human immunodeficiency virus infection 9.Abuse of alcohol or drugs (included past history) 10.Bleeding, in the tendency to bleeding, and family history and past history of bleeding disorders 11.Somebody who are directed by principle investigator and employees in Hamamatsu University hospital 12.Any serious medical or psychiatric illness that could, in the opinion of the investigator, potentially interfere with the completion of treatment according to this protocol.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Safety of TM5509
Secondary Outcome Measures
NameTimeMethod
Pharmacokinetics and pharmacodynamics of TM5509
© Copyright 2025. All Rights Reserved by MedPath